[22] While travel clinics only see a small proportion of patients from HBV-risk countries or those who VFRs within the population, they broaden the chronic HBV identification as well as immunization. A pre-departure survey conducted at Boston Logan International Airport found that about 16% of respondents received travel health advice from travel clinics although the proportion was

<2% among VFRs.[23] Education of travelers from HBV-risk countries along with their screening and vaccination can lead to dissemination of information to their contacts and communities. Low clinician awareness of HBV is a major barrier to screening and vaccination in travel clinics. Other possible barriers to screening and vaccination Dorsomorphin in travel clinics include time to departure and trip length, practice preference for minimal laboratory usage, cost and ability of patients to afford the test, perception that Ruxolitinib ic50 testing would be done elsewhere, clinician time constraints, and sometimes language barriers (Table 3). Limitations of this analysis include the need to exclude records

missing birth country information and data for travelers from HBV-risk countries. Other missing data led to varying denominators throughout the analysis. Another limitation is the data aggregation that leads to generalized interpretation of results, less precise than interpretation of each patient’s specific results. Varied approaches to obtaining past test results and testing at travel clinics

complicated analysis of serologic results. Some travelers were tested previously and also during the clinic visit, possibly because of the results being unavailable at the time of clinic visit or concern for recent exposure, although the small number (n = 14) unlikely had substantial influence overall. Travelers were included Fossariinae in the database only once even if they had multiple visits for vaccine series, though a small number could have repeat entries if seen for another trip that was not previously addressed. The lower testing rate of women in travel clinics may be attributed to the assumption that women undergo perinatal testing, but the database contained no information to assess this hypothesis. Additionally, health insurance information was unavailable to analyze financial constraints regarding testing and immunization. Speaking a non-English primary language did not seem to deter testing given the higher testing rate in this group than in English speakers, but data were lacking on interpreter usage. The US CDC’s recommendation to screen for chronic HBV in persons born in regions with HBsAg prevalence ≥2% has expanded testing to a larger population. The aforementioned IOM report identified deficiencies in knowledge and awareness, surveillance, immunization, and services for viral hepatitis in the United States, and recommended strategies to optimize prevention and control of hepatitis B and C.